Selected Publications & Posters
American College of Rheumatology Annual Scientific Meeting
Poster Presentation, October 2008
Targeting CD70 for the treatment of autoimmune disorders
McEarchern, J.A., et.al.
European Organization for Research and Treatment of
Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR)
International Conference on Molecular Targets and Cancer Therapeutics
Poster Presentations, October 2008
Potent antitumor activity of the anti-CD19 auristatin antibody-drug conjugate
SGN-19A in rituximab sensitive and resistant lymphomas
Gerber, H., et.al.
Combination of the anti-CD30-auristatin E antibody-drug conjugate SGN-35 with
chemotherapy improves antitumor activity in Hodgkin lymphoma
Oflazoglu, E., et.al.
Novel peptide linkers for highly potent antibody-auristatin conjugates
Doronina, S.O., et.al.
International Conference on Malignant Lymphoma
Oral Presentations, June 2008
SGN-40 shows
evidence of activity in patients with relapsed non-Hodgkin's lymphoma: final
results of a phase I dose-escalation study
Advani, R., et.al.
Objective
responses in a phase I dose-escalation study of SGN-35 in patients with
relapsed/refractory Hodgkin lymphoma
Younes, A., et.al.
American Society of Clinical Oncology (ASCO) Annual
Meeting
Poster Presentation, June 2008
Objective responses in a phase I dose-escalation study of SGN-35, a novel
antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or
refractory Hodgkin lymphoma (Abstract #8526)
Younes, A., et.al.
Engineered anti-CD70 antibody with multiple effector functions exhibits in
vitro and in vivo antitumor activities
McEarchern, J.A., Oflazoglu, E., Francisco, L., McDonagh, C.F., Gordon, K.A.,
Stone, I., Klussman, K., Turcott, E., van Rooijen, N., Carter, P., Grewal, I.S.,
Wahl, A.F., Law, C.-L.
Blood 2007
Engineered antibody-drug conjugates with defined sites and stoichiometries of
drug attachment
McDonagh, C.F., Turcott, E., Westendorf, L., Webster, J.B., Alley, S.C.,
Kim, K., Andreyka, J., Stone, I., Hamblett, K.J., Francisco, J.A., Carter, P.
Protein Engineering, Design & Selection 2006
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a
potential therapeutic target for anti-CD70 antibody-drug conjugates
Law, C.-L., Gordon, K.A., Toki, B.E., Yamane, A.K., Hering, M.A., Cerveny,
C.G., Petroziello, J.M., Ryan, M. C., Smith, L., Simon, R., Sauter, G.,
Oflazoglu, E., Doronina, S.O., Meyer, D.L., Francisco, J.A., Carter, P., Senter,
P.D., Copland, J.A., Wood, C.G., Wahl, A.F.
Cancer Research 2006, 66:2328-2337
Enhanced activity of monomethylauristatin F through monoclonal antibody
delivery: effects of linker technology on efficacy and toxicity
Doronina, S.O., Mendelsohn, B.A., Bovee, T.D., Cerveny, C.G., Alley, S.C.,
Meyer, D.L., Oflazoglu, E., Toki, B.E., Sanderson, R.J., Zabinski, R.F., Wahl,
A.F., Senter, P.D.
Bioconjugate Chemistry 2006, 17:114-124
Lysosomal trafficking and cysteine protease metabolism confer target-specific
cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
Sutherland, M.S.K., Sanderson, R.J., Gordon, K.A., Andreyka, J., Cerveny, C.G.,
Yu, C., Lewis, T.S., Meyer, D.L., Zabinski, R.F., Doronina, S.O., Senter, P.D.,
Law, C.-L., Wahl, A.F.
Journal of Biological Chemistry 2006
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40
SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications
Tai, Y-T., Li, X-F., Catley, L., Coffey, R., Breitkreutz, I., Bae, J., Song, W.,
Podar, K., Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., Treon,
S.P., Grewal, I.S., Munshi, N.C., Anderson, K.C.
Cancer Research 2005, 65:11712-11720
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A.M., Senter, P.D.
Nature Biotechnology 2005, 23:1137-1146
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody,
SGN-40
Law, C.-L., Gordon, K.A., Collier, J., Klussman, K., McEarchern, J.A., Cerveny,
C.G., Mixan, B.J., Lee, W.P., Lin, Z., Valdez, P., Wahl, A.F., Grewal, I.S.
Cancer Research 2005, 65:8331-8338
Reduction-Alkylation Strategies for the Modification of Specific Monoclonal
Antibody Disulfides
Sun, M.M.C., Beam, K.S., Cerveny, C.G., Hamblett, K.J., Blackmore, R.S., Torgov,
M.Y., Handley, F.G.M., Ihle, N.C., Senter, P.D., Alley, S.C.
Bioconjugate Chemistry 2005, 16:1282-1290
In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin
immunoconjugate
Sanderson, R.J., Hering, M.A., James, S.F., Sun, M.M.C., Doronina, S.O., Siadak,
A.W., Senter, P.D., Wahl, A.F.
Clinical Cancer Research 2005, 11:843-852
Generation of an intensely potent anthracycline by a monoclonal antibody-β-galactosidase
conjugate
Torgov, M.Y., Alley, S.C., Cerveny, C.G., Farquhar, D., Senter, P.D.
Bioconjugate Chemistry 2005, 16:714-721
Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to
conventional chemotherapeutics
Cerveny, C.G., Law, C.-L., McCormick, R.S., Lenox, J.S., Hamblett, K.J.,
Westendorf, L.E., Yamane, A.K., Petroziello, J.M., Francisco, J.A., Wahl, A.F.
Leukemia 2005, 19:1648-1655
Efficient
elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates
Law, C.-L., Cerveny, C.G., Gordon, K.A., Klussman, K., Mixan, B.J., Chace, D.F.,
Meyer, D.L., Doronina, S.O., Siegall, C.B., Francisco, J.A., Senter, P.D., Wahl,
A.F.
Clinical Cancer Research 2004, 10:7842-7851
Effects of drug loading on the antitumor activity of a monoclonal
antibody-drug conjugate
Hamblett, K.J., Senter, P.D., Chace, D.F., Sun, M.M.C., Lenox, J., Cerveny, C.G.,
Kissler, K.M., Bernhardt, S.X., Kopcha, A.K., Zabinski, R.F., Meyer, D.L.,
Francisco, J.A.
Clinical Cancer Research 2004, 10:7063-7070
Secondary
mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization
via the lysosome pathway
Klussman, K., Mixan, B.J., Cerveny, C.G., Meyer, D.L., Senter, P.D., Wahl, A.F.
Bioconjugate Chemistry 2004, 15:765-773
Suppression
subtractive hybridization and expression profiling identifies a unique set of
genes overexpressed in non-small-cell lung cancer
Petroziello, J., Yamane, A., Westendorf, L., Thompson, M., McDonagh, C.,
Cerveny, C., Law, C.L., Wahl, A., Carter, P.
Oncogene 2004, 23:7734-7745
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity
in human multiple myeloma cells: clinical implications
Tai, Y.-T., Catley, L.P., Mitsiades, C.S., Burger, R., Podar, K., Shringpaure,
R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., Richardson, P.,
Treon, S.P., Munshi, N.C., Anderson, K.C.
Cancer Research 2004, 64:2846-2852
Identification and validation of cell surface antigens for antibody targeting in
oncology
Carter, P., Smith, L., Ryan, M.
Endocrine-Related Cancer 2004, 11:659-687
Development
of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S.O., Toki, B.E., Torgov, M.Y., Mendelsohn, B.A., Cerveny, C.G., Chace,
D.F., DeBlanc, R.L., Gearing, R.P., Bovee, T.D., Siegall, C.B., Francisco, J.A.,
Wahl, A.F., Meyer, D.L, Senter, P.D.
Nature Biotechnology 2003, 21:778-784
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and
selective antitumor activity
Francisco, J.A., Cerveny, C.G., Meyer, D.L., Mixan, B.J., Klussman, K., Chace,
D.F., Rejniak, S.X., Gordon, K.A., DeBlanc, R., Toki, B.E., Law, C.L., Doronina,
S.O., Siegall, C.B., Senter, P.D., Wahl, A.F.
Blood 2003, 102:1458-1465
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous
antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells
Hayashi, T., Treon, S.P., Hideshima, T., Tai, Y.-T., Akiyama, M., Richardson,
P., Chauhan, D., Grewal, I.S., Anderson, K.C.
British Journal of Haematology 2003, 121:592-596
The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation
in vitro and affects antitumor activity in models of Hodgkin’s disease
Wahl, A.F., Klussman, K.K., Thompson, J.D., Chen, J.H., Francisco, L.V., Risdon, G.,
Chace, D.F., Siegall, C.B., Francisco, J.A.
Cancer Research 2002, 62:3736-3742
Activation-induced
cell death of aggressive histology lymphomas by CD40 stimulation: induction of
bax
Szocinski, J.L., Khaled, A.R., Hixon, J., Halverson, D., Funakoshi, S., Fanslow,
W.C., Boyd, A., Taub, D.D., Durum S.K., Siegall, C.B., Longo, D.L., Murphy, W.J.
Blood 2002, 100:217-223
Agonistic properties and
in vivo antitumor activity of the anti-CD40 antibody SGN-14
Francisco, J.A., Donaldson, K.L., Chace, D.F., Siegall, C.B., Wahl, A.F.
Cancer Research 2000, 60:3225-3231